MENSNasdaqPharmaceutical Preparations
Jyong Biotech Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$1.93+0.09 (+4.89%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Jyong Biotech's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perfect Minds Co., Ltd | 25,349,500 | 33.34% | 13D (active) | Jun 16, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Fu-Feng Kuo | CEO, Director, 10% owner | 25,349,500 | 33.34% | Apr 8, 2026 |
| Wei (Vivi) Zhang | CFO | – | – | Apr 14, 2026 |
| Ming Tsan Hsu | Director | 3,000 | 0.00% | Apr 1, 2026 |
| Hung-Shu Fan | Director | – | – | Apr 1, 2026 |
| Feng-Lin Hsu | Director | 3,000 | 0.00% | Apr 1, 2026 |
| Pang-Chieh Chi | Director | – | – | Apr 1, 2026 |